Table 4.
Urinary biomarkers in renal cell carcinoma patients on small molecule VEGF inhibitors only (N=29) and bevacizumab only (N=11) compared with controls not on VEGF inhibitors with median (IQR) and p value for comparison by Wilcoxon test
| Biomarker | Non- VEGF inhibitor controls (N=40) | Small molecule VEGF inhibitors (N=29) | P value vs. controls | Bevacizumab (N=11) | P value vs. controls |
|---|---|---|---|---|---|
| NOx /Cr, umol/mg | 0.62 (0.42–0.84) | 0.36 (0.26–0.58) | 0.01 | 0.67 (0.45–1.41) | 0.52 |
| cGMP/Cr, pmol/ug | 0.39 (0.30–0.62) | 0.25 (0.22–0.36) | 0.003 | 0.47 (0.19–0.77) | 0.66 |
| PGE2/Cr, pg/ug | 1.31 (0.99–1.69) | 1.08 (0.78–1.82) | 0.49 | 1.50 (0.80–2.54) | 0.78 |
| cAMP/Cr, pmol/ug | 5.12 (3.88–6.17) | 5.09 (4.68–7.43) | 0.15 | 4.71 (4.27–6.49) | 0.18 |
| 6-keto PGF 1α/Cr, pg/ug | 1.13 (0.75–1.55) | 1.03 (0.85–1.31) | 0.86 | 1.26 (0.94–2.22) | 0.98 |
| ACR, mg/g | 4.6 (0–35.6) | 18.5 (0–232.3) | 0.03 | 18.3 (7.9–607.9) | 0.04 |
VEGF denotes vascular endothelial growth factor; IQR, interquartile range; NOx, nitric oxide; Cr, creatinine; cGMP, cyclic GMP; PGE2, prostaglandin E2; cAMP, cyclic AMP; ACR, albumin:creatinine ratio